Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-KRd in newly diagnosed high-risk multiple myeloma
2016-000432-17Phase 2Active
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of isatuximab, carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: MRD negativity after induction and consolidation. Started Sep 2016; status: active.
02
Drugs
isatuximabcarfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-000432-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000432-17.